High incidence of non-upper aerodigestive primary tumors in patients with esophageal cancer

R. Spector, I. Liphshitz, M. Barchana, Y. Kundel, N. Wasserberg, S. Lelcuk, A. Sulkes, Baruch Brenner

Research output: Contribution to journalArticlepeer-review

Abstract

Earlier reports have described an association between esophageal cancer (EC) and high incidence of other primary tumors (OPTs) of the upper aerodigestive tract and breast cancer. We evaluated the incidence of non-upper aerodigestive OPTs among Israeli EC patients; 2328 EC patients were retrieved from the Israeli National Cancer Registry between 1980 and 2004. The relative risk of OPTs for EC patients was measured using standardized incidence ratio (SIR). Two cohorts, Israeli National Cancer Registry registered colorectal cancer (CRC) patients and the general Israeli population, were used for reference; 297 EC patients (12.7%) had OPTs, including breast (18.9%), CRC (16.2%), prostate (8.8%), and bladder (8.4%) cancers. Upper aerodigestive OPTs were less common. Most OPTs were identified before (74.4%) or simultaneously with (13.8%) EC diagnosis. The median time interval between OPTs diagnoses and EC development was 6.0years. The incidence of OPTs was significantly higher among EC patients compared with CRC patients (SIR: 2.05, P < 0.01) or the general Israeli population (SIR: 3.90, 95% CI: 3.46-4.34, P < 0.01) regardless of gender or tumor histology. Patients with EC have high incidence of non-upper aerodigestive malignancies. Unlike previous reports, the distribution of OPTs in EC seems to represent the relative incidences of these cancers in the western populations.

Original languageEnglish
Pages (from-to)718-722
Number of pages5
JournalDiseases of the Esophagus
Volume21
Issue number8
DOIs
StatePublished - 2008

Keywords

  • Esophageal cancer
  • Other primary tumors
  • Upper aerodigestive tumors

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'High incidence of non-upper aerodigestive primary tumors in patients with esophageal cancer'. Together they form a unique fingerprint.

Cite this